|
|
| 16-Jan-2001 |
Endovasc Announces the Successful Completion of Phase I Human Trials and Enters Phase II for Liprostin
|
|
MONTGOMERY, Texas--(BW HealthWire)--Jan. 16, 2001--Endovasc Ltd. Inc. (OTCBB:ENDV - news) today announced the successful completion of the Phase I trials for its patented drug Liprostin(TM). Healthy volunteers were the subjects for the "dose tolerance" tests, conducted by Dr. Dennis A. Ruff at his clinic in San Antonio.
Dr. Ruff and his staff have been part of 250 clinical trials, and Dr. Ruff has been principal investigator on studies covering hypertension, diabetes, OA, CHF, CAD, AFIB and erosive esophagitis, to name just a few. Dr. Ruff said, "Liprostin(TM) was well tolerated and even at maximum tolerated dose (MTD) levels caused few side effects, all of which were minimal and very short term."
In a statement regarding the MTD determined by these tests, Dr. David P. Summers, Ph.D., chairman and CEO of Endovasc, said, "This clears the way for Endovasc to take the next major step of taking Liprostin(TM) forward into Phase II trials. Phase II will treat patients who have critical limb ischemia and will be conducted by Dr. Richard W. Smalling of the University of Texas Center for Cardiovascular Medicine in Houston."
Liposomal Prostaglandin E1, (PGE-1) known by its trademark, Liprostin(TM), is a patented drug and delivery system (liposomes), which can be delivered to specific vascular areas for treatment of occlusive vascular disease and other indications. Liprostin(TM), delivered to angioplasty sites, could greatly reduce restenosis or new blockage and can save the healthcare system billions of dollars, and reduce the number of patients experiencing repeat angioplasty procedures.
Endovasc Ltd. Inc. is a biopharmaceutical company specializing in the development and manufacturing of drug delivery technology. The company develops liposomal encapsulations of drugs that have already shown safety and efficacy. In the liposome form, dosage and time-release of the drugs can be controlled and time-released, for the treatment of vascular disease of the heart, limbs and clinical areas of the circulatory system. The company's products and processes are covered by patent and trade secrets for competing in a $2 billion market, and it has recently met all SEC reporting requirements to be listed on the NASD OTC Bulletin Board.
Contact:
Barbara J. Richardson
Endovasc Ltd., Inc.
936-448-2222
www.endovasc.com
|
|
|
|
|
